Study to Evaluate the Efficacy of Response-adapted Strategy in Follicular Lymphoma
- Conditions
- Follicular Non-Hodgkin's Lymphoma
- Interventions
- Drug: R-CHOP or R-bendamustineDrug: Standard MaintenanceDrug: Maintenance weekly x4Drug: Observation
- First Posted Date
- 2014-02-14
- Last Posted Date
- 2022-06-21
- Lead Sponsor
- Fondazione Italiana Linfomi - ETS
- Target Recruit Count
- 807
- Registration Number
- NCT02063685
- Locations
- 🇮🇹
Irccs Istituto Clinico Humanitas, Rozzano, Milano, Italy
🇮🇹Irst - Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori - Sede Di Meldola (Fc), Meldola, Forlì Cesena, Italy
🇮🇹Fondazione IRCCS Milano INT, Milano, MI, Italy
Rituximab Plus Bendamustine as Front Line Treatment in Frail Elderly (>70 Years) Patients With DLBCL: a Phase II Multicenter Study of the FIL
- Conditions
- Diffuse Large B-cell Lymphoma
- Interventions
- Drug: Bendamustine+Rituximab
- First Posted Date
- 2013-11-21
- Last Posted Date
- 2013-11-21
- Lead Sponsor
- Fondazione Italiana Linfomi - ETS
- Target Recruit Count
- 49
- Registration Number
- NCT01990144
- Locations
- 🇮🇹
Ospedale Generale Di Zona, Civitanova Marche, Macerata, Italy
🇮🇹Irccs Centro Di Riferimento Oncologico (Cro), Aviano, Pordenone, Italy
🇮🇹A.O. Universitaria S. Martino Di Genova, Genova, Italy
A Phase II Study for Patients With Indolent Non-follicular Non-Hodgkin's Lymphoma
- Conditions
- Indolent Non-follicularNon-Hodgkin's Lymphoma
- Interventions
- First Posted Date
- 2013-08-27
- Last Posted Date
- 2017-10-13
- Lead Sponsor
- Fondazione Italiana Linfomi - ETS
- Target Recruit Count
- 73
- Registration Number
- NCT01929265
- Locations
- 🇮🇹
SC Ematologia - AO SS. Antonio e Biagio e C. Arrigo, Alessandria, AL, Italy
🇮🇹Divisione di Ematologia Ospedale Niguarda, Milano, MI, Italy
🇮🇹Centro Oncologico Modenese, Modena, MO, Italy
A Phase III Multicenter, Randomized Study Comparing RIT Vs ASCT in Patients With Relapsed/Refractory (FL)
- Conditions
- Relapsed Follicular Lymphoma
- Interventions
- Other: ZEVALIN
- First Posted Date
- 2013-04-09
- Last Posted Date
- 2023-12-14
- Lead Sponsor
- Fondazione Italiana Linfomi - ETS
- Target Recruit Count
- 159
- Registration Number
- NCT01827605
- Locations
- 🇮🇹
IRCC Onco-Ematologia, Candiolo, Italy
🇮🇹Spedali Civili, Brescia, Italy
🇮🇹Emat Univ - Città della salute e della scienza di Torino, Torino, TO, Italy
Phase II Study of Gemcitabine+Romidepsin in the Relapsed/Refractory Peripheral T-cell Lymphoma Patients
- First Posted Date
- 2013-04-02
- Last Posted Date
- 2019-10-14
- Lead Sponsor
- Fondazione Italiana Linfomi - ETS
- Target Recruit Count
- 20
- Registration Number
- NCT01822886
- Locations
- 🇮🇹
A.O. Universitaria Citta' Della Salute E Della Scienza Di Torino, Torino, Italy
🇮🇹A.O. SS. Antonio e Biagio e C. Arrigo, Alessandria, Italy
🇮🇹Istituto di Ematologia ed Oncologia Medica A. Seragnoli Policlinico S. Orsola, Bologna, Italy
Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Eligible to Transplantation. BR-DHAP Versus R-DHAP.
- Conditions
- Diffuse Large B-cell Lymphoma RefractoryDiffuse Large B-cell Lymphoma Recurrent
- Interventions
- Drug: R-DHAPDrug: BR-DHAP
- First Posted Date
- 2013-03-06
- Last Posted Date
- 2022-06-08
- Lead Sponsor
- Fondazione Italiana Linfomi - ETS
- Target Recruit Count
- 108
- Registration Number
- NCT01805557
- Locations
- 🇮🇹
ASST Grande Ospedale Metropolitano Niguarda - SC Ematologia, Milano, MI, Italy
🇮🇹A.O. SS. Antonio e Biagio e C. Arrigo, Alessandria, Italy
🇮🇹Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori-Ematologia, Meldola, Forlì-Cesena, Italy
Bendamustine/Lenalidomide/Rituximab: Combination as a Second-Line Therapy for 1st Relapsed-Refractory MCL
- Conditions
- Mantle Cell Lymphoma
- Interventions
- Drug: Bendamustine, Lenalidomide, Rituximab
- First Posted Date
- 2012-11-29
- Last Posted Date
- 2018-03-09
- Lead Sponsor
- Fondazione Italiana Linfomi - ETS
- Target Recruit Count
- 42
- Registration Number
- NCT01737177
- Locations
- 🇮🇹
Centro di riferimento Oncologico CRO Aviano, Aviano, Pordenone, Italy
🇮🇹IRCCS-Centro di Riferimento Oncologico UO di Ematologia e Trapianto Cellule Staminali, Rionero in Vulture, Potenza, Italy
🇮🇹Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRST Meldola, Meldola, Forlì Cesena, Italy
Phase II Study of Age-Adjusted Rituximab, Bendamustine, Cytarabine as Induction Therapy in Older Patients With MCL
- Conditions
- Mantle Cell Lymphoma
- Interventions
- Drug: Rituximab, Bendamustine, Cytarabine.
- First Posted Date
- 2012-08-10
- Last Posted Date
- 2022-08-09
- Lead Sponsor
- Fondazione Italiana Linfomi - ETS
- Target Recruit Count
- 57
- Registration Number
- NCT01662050
- Locations
- 🇮🇹
AOU Careggi, Firenze, FI, Italy
🇮🇹IRCCS Ospedale Oncologico, Bari, BA, Italy
🇮🇹Ospedale degli Infermi di Rimini, Rimini, RN, Italy
Oral Panobinostat Adult Patients DLBCL Relapsed/Refractory Stem Cell Transfusion (ASCT) or Not Eligible for ASCT
- First Posted Date
- 2012-02-01
- Last Posted Date
- 2019-11-22
- Lead Sponsor
- Fondazione Italiana Linfomi - ETS
- Target Recruit Count
- 35
- Registration Number
- NCT01523834
- Locations
- 🇮🇹
Azienda Ospedaliera SS. Antonio e Biagio e C. Arrigo, Alessandria, Italy
🇮🇹Istituto di Ematologia ed Oncologia Medica A. Seragnoli Policlinico S. Orsola, Bologna, Italy
🇮🇹Ospedale Umberto I - DH Oncoematologico, Nocera Inferiore, Italy
A Multi-centre Study of MBVD in Elderly and/or Cardiopathic Patients Affected by Hodgkin's Lymphoma (HL)
- Conditions
- Hodgkin Lymphoma
- Interventions
- Drug: MBVD (Myocet+BVD)
- First Posted Date
- 2012-02-01
- Last Posted Date
- 2016-08-04
- Lead Sponsor
- Fondazione Italiana Linfomi - ETS
- Target Recruit Count
- 50
- Registration Number
- NCT01523847
- Locations
- 🇮🇹
Policlinico S. Orsola Malpighi, Bologna, Italy
🇮🇹Ospedale Guglielmo da Saliceto, Piacenza, Italy
🇮🇹SC Medicina trasfusionale ed Ematologia Ospedale civile di Ivrea, Ivrea, Torino, Italy